Drug Fix: MFN Finds Mid-Size Companies And More Vaccine Policy Moves

Pink Sheet Executive Editor Derrick Gingery, Senior Reporter Maaisha Osman, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs consider the potential differences between Most Favored Nation drug pricing agreements for small and mid-size companies and the largest pharmas (1:03), as well as the impact of potential vaccine policy changes on the US public health apparatus (15:10).

More On These Topics From The Pink Sheet

MFN Deal Impact Unclear As White House Ready To Announce Agreements With Mid-Size Pharmas: insights.citeline.com/pink-sheet/market-access…

HHS Builds A Legal Firewall Around Its Next Vaccine Moves With RFI On Federal Categories: insights.citeline.com/pink-sheet/vaccines/hhs-…